Discover
DMRA
Damora Therapeutics, Inc.
27.86
2 x 21.68
2 x 36.68
bid
ask
-
1.14
3.93%
10:26 AM
timesize
| Ytd | 21.08% | |
| 1y | 776.10% |
27.80
day range
28.93
2.45
52 week range
38.33
| Open | 28.93 | Prev Close | 29.00 | Low | 27.80 | High | 28.93 | Mkt Cap | 1.72B |
| Vol | 29.90K | Avg Vol | 565.97K | EPS | -0.26 | P/E | N/A | Forward P/E | -13.54 |
| Beta | 1.47 | Short Ratio | 11.63 | Inst. Own | 105.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 29.04 | 200-d Avg | 25.96 | 1yr Est | 44.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.52 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.41 | -0.39 | 0.02 | 5.79% |
| 2026-05-12 | 2026-03 | -0.21 | -0.62 | -0.41 | -195.24% |
| 2026-03-18 | 2025-12 | -0.14 | -3.24 | -3.1 | -2216.35% |
| 2025-11-06 | 2025-09 | -0.1 | -2.36 | -2.26 | -2337.76% |
| 2025-08-05 | 2025-06 | 0 | -2.6 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-30 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-07-27 | Jefferies | Upgrade | Buy | |
| 2026-07-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-11 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-05-28 | Wedbush | Upgrade | Outperform |
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BRUNO JULIANNE | Director | 137.03K | Conversion of Exercise of derivative security |
| 2026-02-08 | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-01-01 | FIRMANI LORI | Chief Financial Officer | 931.00 | Sale |
| 2026-01-04 | HEWES LEMUEL BECKER | Officer | 264.63K | Stock Award(Grant) |
| 2026-03-29 | JARRETT A JENNIFER | Chief Executive Officer | 500.00K | Stock Award(Grant) |
| 2026-01-04 | SATTARZADEH SHERWIN | Chief Operating Officer | 190.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Price (T.Rowe) Associates Inc | 48.74K | 1.41M | 0.08% |
| 2026-06-29 | Rothschild Investment LLC | 34.00 | 986.00 | 0.00% |
| 2026-06-29 | Harbour Investments, Inc. | 40.00 | 1.16K | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | GLOBAL X FUNDS-Global X Russell 2000 ETF | 25.56K | 741.18K | 0.04% |
| 2026-07-30 | ProShares Trust-ProShares Russell 2000 High Income ETF | 2.82K | 81.72K | 0.00% |
| 2026-07-30 | ProShares Trust-ProShares UltraPro Russell2000 | 1.79K | 51.91K | 0.00% |
| 2026-07-30 | ProShares Trust-ProShares Ultra Russell2000 | 1.66K | 48.20K | 0.00% |
| 2026-07-30 | ProShares Trust-ProShares Hedge Replication ETF | 52.00 | 1.51K | 0.00% |
| 2026-07-30 | -ProShares Russell 2000 Dynamic Buffer ETF | 17.00 | 493.00 | 0.00% |